As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald ...

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported fourth-quarter earnings of $15.3 million. On a per-share basis, the Rockville, Maryland ...

the estimate revisions trend for Supernus: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status ...

Reports Q4 revenue $174.2M ... and strong growth in operating earnings,” said Jack Khattar, President and CEO of Supernus (SUPN). “In 2025, we look forward to continued Qelbree growth ...

Is Supernus Pharmaceuticals a buy or sell going into earnings? Read our full analysis here ... Click here to claim your Special Free Report on a fallen angel growth story that is already recovering ...